Does the media prefer BBNX or PLSE?

In the previous week, Beta Bionics had 32 more articles in the media than Pulse Biosciences. MarketBeat recorded 34 mentions for Beta Bionics and 2 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.82 beat Beta Bionics' score of 0.06 indicating that Pulse Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pulse Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBNX or IRTC?

In the previous week, Beta Bionics had 29 more articles in the media than iRhythm Technologies. MarketBeat recorded 34 mentions for Beta Bionics and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.20 beat Beta Bionics' score of 0.06 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iRhythm Technologies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, BBNX or ATRC?

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 8.51 -$73.20M -$1.65 N/A AtriCure $534.53M 5.25 -$11.45M $0.21 262.57

Is BBNX or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -61.31% -26.30% -23.25% AtriCure 1.85% 2.34% 1.77%

Does the media prefer BBNX or ATRC?

In the previous week, Beta Bionics had 29 more articles in the media than AtriCure. MarketBeat recorded 34 mentions for Beta Bionics and 5 mentions for AtriCure. Beta Bionics' average media sentiment score of 0.06 beat AtriCure's score of -0.09 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TMDX or BBNX?

In the previous week, Beta Bionics had 28 more articles in the media than TransMedics Group. MarketBeat recorded 34 mentions for Beta Bionics and 6 mentions for TransMedics Group. Beta Bionics' average media sentiment score of 0.06 beat TransMedics Group's score of -0.12 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 1 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBNX or BFLY?

In the previous week, Beta Bionics had 27 more articles in the media than Butterfly Network. MarketBeat recorded 34 mentions for Beta Bionics and 7 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 0.74 beat Beta Bionics' score of 0.06 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 2 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Butterfly Network 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Beta Bionics (BBNX) Competitors

$18.95 -0.01 (-0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$18.93 -0.02 (-0.08%)

As of 04:15 PM Eastern

Compare

BBNX vs. PLSE, IRTC, ATRC, TMDX, and BFLY

Should you buy Beta Bionics stock or one of its competitors? Beta Bionics's main competitors and comparable companies include Pulse Biosciences (PLSE), iRhythm Technologies (IRTC), AtriCure (ATRC), TransMedics Group (TMDX), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Beta Bionics compare to Pulse Biosciences?

Beta Bionics (NASDAQ:BBNX) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Beta Bionics had 32 more articles in the media than Pulse Biosciences. MarketBeat recorded 34 mentions for Beta Bionics and 2 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.82 beat Beta Bionics' score of 0.06 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	2 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulse Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beta Bionics has a beta of 3.39, meaning that its share price is 239% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Beta Bionics has a net margin of -61.31% compared to Pulse Biosciences' net margin of -6,755.78%. Beta Bionics' return on equity of -26.30% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Pulse Biosciences has lower revenue, but higher earnings than Beta Bionics. Pulse Biosciences is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.51	-$73.20M	-$1.65	N/A
Pulse Biosciences	$350K	9,689.49	-$72.78M	-$1.18	N/A

77.0% of Pulse Biosciences shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Beta Bionics currently has a consensus target price of $22.91, indicating a potential upside of 20.83%. Pulse Biosciences has a consensus target price of $50.20, indicating a potential upside of 4.80%. Given Beta Bionics' higher possible upside, equities research analysts clearly believe Beta Bionics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Beta Bionics beats Pulse Biosciences on 9 of the 17 factors compared between the two stocks.

How does Beta Bionics compare to iRhythm Technologies?

Beta Bionics (NASDAQ:BBNX) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

In the previous week, Beta Bionics had 29 more articles in the media than iRhythm Technologies. MarketBeat recorded 34 mentions for Beta Bionics and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.20 beat Beta Bionics' score of 0.06 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	2 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics has a beta of 3.39, indicating that its stock price is 239% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Beta Bionics currently has a consensus price target of $22.91, indicating a potential upside of 20.83%. iRhythm Technologies has a consensus price target of $179.93, indicating a potential upside of 63.02%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRhythm Technologies has higher revenue and earnings than Beta Bionics. iRhythm Technologies is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.51	-$73.20M	-$1.65	N/A
iRhythm Technologies	$747.14M	4.87	-$44.55M	-$0.43	N/A

iRhythm Technologies has a net margin of -1.69% compared to Beta Bionics' net margin of -61.31%. iRhythm Technologies' return on equity of 10.11% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
iRhythm Technologies	-1.69%	10.11%	1.53%

Summary

iRhythm Technologies beats Beta Bionics on 11 of the 15 factors compared between the two stocks.

How does Beta Bionics compare to AtriCure?

Beta Bionics (NASDAQ:BBNX) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
AtriCure	1.85%	2.34%	1.77%

In the previous week, Beta Bionics had 29 more articles in the media than AtriCure. MarketBeat recorded 34 mentions for Beta Bionics and 5 mentions for AtriCure. Beta Bionics' average media sentiment score of 0.06 beat AtriCure's score of -0.09 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	2 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.51	-$73.20M	-$1.65	N/A
AtriCure	$534.53M	5.25	-$11.45M	$0.21	262.57

Beta Bionics currently has a consensus target price of $22.91, suggesting a potential upside of 20.83%. AtriCure has a consensus target price of $53.30, suggesting a potential downside of 3.34%. Given Beta Bionics' higher probable upside, analysts clearly believe Beta Bionics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Beta Bionics has a beta of 3.39, meaning that its share price is 239% more volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

99.1% of AtriCure shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 4.0% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AtriCure beats Beta Bionics on 9 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

TransMedics Group has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.55	$190.29M	$3.89	20.51
Beta Bionics	$100.25M	8.51	-$73.20M	-$1.65	N/A

TransMedics Group currently has a consensus target price of $121.10, indicating a potential upside of 51.77%. Beta Bionics has a consensus target price of $22.91, indicating a potential upside of 20.83%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

In the previous week, Beta Bionics had 28 more articles in the media than TransMedics Group. MarketBeat recorded 34 mentions for Beta Bionics and 6 mentions for TransMedics Group. Beta Bionics' average media sentiment score of 0.06 beat TransMedics Group's score of -0.12 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	1 Very Positive mention(s)	2 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.39, suggesting that its stock price is 239% more volatile than the broader market.

TransMedics Group has a net margin of 22.69% compared to Beta Bionics' net margin of -61.31%. TransMedics Group's return on equity of 15.88% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Beta Bionics	-61.31%	-26.30%	-23.25%

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

TransMedics Group beats Beta Bionics on 10 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to Butterfly Network?

Beta Bionics (NASDAQ:BBNX) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Beta Bionics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.51	-$73.20M	-$1.65	N/A
Butterfly Network	$97.61M	24.33	-$77.06M	-$0.29	N/A

Beta Bionics has a net margin of -61.31% compared to Butterfly Network's net margin of -66.74%. Beta Bionics' return on equity of -26.30% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Butterfly Network	-66.74%	-33.99%	-22.96%

Beta Bionics currently has a consensus price target of $22.91, suggesting a potential upside of 20.83%. Butterfly Network has a consensus price target of $8.54, suggesting a potential downside of 4.21%. Given Beta Bionics' higher probable upside, research analysts plainly believe Beta Bionics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

37.9% of Butterfly Network shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 22.0% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Beta Bionics has a beta of 3.39, suggesting that its share price is 239% more volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

In the previous week, Beta Bionics had 27 more articles in the media than Butterfly Network. MarketBeat recorded 34 mentions for Beta Bionics and 7 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 0.74 beat Beta Bionics' score of 0.06 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	2 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Butterfly Network	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beta Bionics beats Butterfly Network on 9 of the 17 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$852.56M	$5.52B	$7.17B	$13.38B
Dividend Yield	N/A	1.79%	2.53%	17.32%
P/E Ratio	-11.48	25.76	274.64	26.20
Price / Sales	8.50	42.32	608.57	90.53
Price / Cash	N/A	32.73	27.22	34.70
Price / Book	2.90	6.04	11.26	6.40
Net Income	-$73.20M	$146.97M	$3.49B	$381.07M
7 Day Performance	-7.65%	-0.96%	-1.68%	-0.65%
1 Month Performance	-2.42%	-4.28%	-5.97%	-4.51%
1 Year Performance	-14.87%	2.47%	8.11%	1.82%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	1.9116 of 5 stars	$18.95 -0.1%	$22.91 +20.9%	-14.8%	$852.56M	$100.25M	N/A	423	Trending News
PLSE Pulse Biosciences	1.948 of 5 stars	$51.63 -0.4%	$50.20 -2.8%	+148.3%	$3.67B	$350K	N/A	116
IRTC iRhythm Technologies	3.4652 of 5 stars	$110.38 -0.4%	$179.93 +63.0%	-37.2%	$3.65B	$747.14M	N/A	2,400	News Coverage Analyst Forecast
ATRC AtriCure	2.621 of 5 stars	$58.38 -3.9%	$53.30 -8.7%	+58.4%	$3.09B	$534.53M	278.01	1,350	Analyst Downgrade
TMDX TransMedics Group	4.5191 of 5 stars	$85.29 +1.7%	$121.10 +42.0%	-31.0%	$2.90B	$605.49M	21.93	898

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. PLSE, IRTC, ATRC, TMDX, and BFLY

How does Beta Bionics compare to Pulse Biosciences?

Summary

How does Beta Bionics compare to iRhythm Technologies?

Summary

How does Beta Bionics compare to AtriCure?

Summary

How does Beta Bionics compare to TransMedics Group?

Summary

How does Beta Bionics compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. PLSE, IRTC, ATRC, TMDX, and BFLY

How does Beta Bionics compare to Pulse Biosciences?

Does the media prefer BBNX or PLSE?

Which has more risk & volatility, BBNX or PLSE?

Is BBNX or PLSE more profitable?

Which has preferable earnings & valuation, BBNX or PLSE?

Do institutionals & insiders have more ownership in BBNX or PLSE?

Do analysts recommend BBNX or PLSE?

Summary

How does Beta Bionics compare to iRhythm Technologies?

Does the media prefer BBNX or IRTC?

Which has more volatility and risk, BBNX or IRTC?

Do analysts rate BBNX or IRTC?

Which has better valuation & earnings, BBNX or IRTC?

Is BBNX or IRTC more profitable?

Summary

How does Beta Bionics compare to AtriCure?

Is BBNX or ATRC more profitable?

Does the media prefer BBNX or ATRC?

Which has stronger valuation and earnings, BBNX or ATRC?

Do analysts prefer BBNX or ATRC?

Which has more risk & volatility, BBNX or ATRC?

Do insiders & institutionals hold more shares of BBNX or ATRC?

Summary

How does Beta Bionics compare to TransMedics Group?

Which has higher valuation & earnings, TMDX or BBNX?

Do analysts rate TMDX or BBNX?

Does the media prefer TMDX or BBNX?

Which has more volatility and risk, TMDX or BBNX?

Is TMDX or BBNX more profitable?

Do insiders & institutionals have more ownership in TMDX or BBNX?

Summary

How does Beta Bionics compare to Butterfly Network?

Which has higher earnings & valuation, BBNX or BFLY?

Is BBNX or BFLY more profitable?

Do analysts prefer BBNX or BFLY?

Do institutionals & insiders hold more shares of BBNX or BFLY?

Which has more risk & volatility, BBNX or BFLY?

Does the media refer more to BBNX or BFLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools